DiaSorin SpA (DIA):医療機器:M&Aディール及び事業提携情報

◆英語タイトル:DiaSorin SpA (DIA) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA904C7083
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:49
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イタリア
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
DiaSorin S.p.A. (DiaSorin) is a medical diagnostics company that develops, manufactures and markets in vitro diagnostics reagent kits and systems. The company develops reagent kits based on Radioimmunometry (RIA), Enzyme Linked Immunosorbent Assays (ELISA) and Chemiluminescence (CLIA) techniques, to enable automatic diagnostic investigation. The company’s products find application in the diagnosis of infectious diseases, bone and mineral disorders, endocrinology, hypertension, oncology, gastrointestinal infections, autoimmune disorders, and neurological and cardiac diseases. DiaSorin markets its products through direct sales force and distributors. It has operations in North America, South America, South Africa, EMEA and Asia. DiaSorin is headquartered at Saluggia, Piemonte, Italy.

DiaSorin SpA (DIA) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
DiaSorin SpA, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
DiaSorin SpA, Medical Equipment Deals By Type, 2012 to YTD 2018 6
DiaSorin SpA, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
DiaSorin SpA, Medical Equipment, Deals By Market, 2012 to YTD 2018 8
DiaSorin SpA, Medical Equipment, Deals Summary, 2012 to YTD 2018 9
DiaSorin SpA, Medical Equipment, Deal Details 10
Asset Purchase 10
DiaSorin Acquires ELISA Immunodiagnostic Business Portfolio from Siemens Healthcare for USD55.3 Million 10
DiaSorin Acquires Molecular and Immunoassay Product Business of Focus Diagnostics from Quest Diagnostics 11
Biotrin International Acquires Molecular Diagnostic Business Of NorDiag For US$10 Million 13
Partnerships 14
Evogen Enters Into Licensing Agreement With Focus Diagnostics For HyBeacons PCR Probe Technology 14
AbD Serotec Enters Into Licensing Agreement With DiaSorin For HuCAL Antibodies 15
DiaSorin Enters into Agreement with Tecan 16
DiaSorin Enters into Agreement with QIAGEN 17
DiaSorin Enters into Agreement with Beckman Coulter 18
DiaSorin Enters into Distribution Agreement with Beckman Coulter Diagnostics 19
Enzo Clinical Enters Into Collaboration Agreement With DiaSorin 20
DiaSorin Forms Joint Venture With Trivitron Healthcare 21
Asset Transactions 22
DiaSorin Acquires Molecular and Immunoassay Product Business of Focus Diagnostics from Quest Diagnostics 22
DiaSorin SpA – Key Competitors 24
DiaSorin SpA – Key Employees 25
DiaSorin SpA – Locations And Subsidiaries 26
Head Office 26
Other Locations & Subsidiaries 26
Recent Developments 28
Financial Announcements 28
Aug 02, 2018: The Board of Directors approves the results for the first half of 2018 28
May 08, 2018: The Diasorin Group Reports Growth in Revenues and Profitability in the First Quarter 2018 32
Nov 09, 2017: Growth In Revenues And Net Profit In Q3 2017. Strong Free Cash Flow Generation. 2017 Guidance Confirmed 35
Aug 03, 2017: Diasorin Group Reports Strong Growth in Revenues and Profitability in Q2 2017 36
May 08, 2017: Diasorin Group Reports Growth In Revenues And Profitability In The First Quarter 2017, Generating A Relevant Free Cash Flow 39
Mar 08, 2017: Net Profit And Cash Generation Reached Record Highs In 2016, Driven By Growth In Revenues And Profitability 41
Product News 44
Jun 12, 2018: Diasorin Introduces Primer Pair Reagents For Use In Molecular Testing: Anaplasma Phagocytophilum, Ehrlichia And Babesia 44
Jun 12, 2018: DiaSorin Molecular Introduces Primer Pair Reagents for A. phagocytophilum, Ehrlichia and Babesia 45
Sep 26, 2017: DiaSorin Molecular Introduces Two Primer Pair Reagents for Streptococcus 46
Jul 28, 2017: Diasorin Launches 3 New Primer Pairs For Use In Molecular Testing: Pneumocystis Jirovecii, Group C Streptococcus, And Group G Streptococcus 47
Other Significant Developments 48
Jun 26, 2017: Diasorin Presents Its 2017-2019 Industrial Plan 48
Appendix 49
Methodology 49
About GlobalData 49
Contact Us 49
Disclaimer 49

List of Tables
DiaSorin SpA, Medical Equipment, Key Facts, 2017 2
DiaSorin SpA, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
DiaSorin SpA, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
DiaSorin SpA, Medical Equipment Deals By Type, 2012 to YTD 2018 6
DiaSorin SpA, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
DiaSorin SpA, Deals By Market, 2012 to YTD 2018 8
DiaSorin SpA, Medical Equipment, Deals Summary, 2012 to YTD 2018 9
DiaSorin Acquires ELISA Immunodiagnostic Business Portfolio from Siemens Healthcare for USD55.3 Million 10
DiaSorin Acquires Molecular and Immunoassay Product Business of Focus Diagnostics from Quest Diagnostics 11
Biotrin International Acquires Molecular Diagnostic Business Of NorDiag For US$10 Million 13
Evogen Enters Into Licensing Agreement With Focus Diagnostics For HyBeacons PCR Probe Technology 14
AbD Serotec Enters Into Licensing Agreement With DiaSorin For HuCAL Antibodies 15
DiaSorin Enters into Agreement with Tecan 16
DiaSorin Enters into Agreement with QIAGEN 17
DiaSorin Enters into Agreement with Beckman Coulter 18
DiaSorin Enters into Distribution Agreement with Beckman Coulter Diagnostics 19
Enzo Clinical Enters Into Collaboration Agreement With DiaSorin 20
DiaSorin Forms Joint Venture With Trivitron Healthcare 21
DiaSorin Acquires Molecular and Immunoassay Product Business of Focus Diagnostics from Quest Diagnostics 22
DiaSorin SpA, Key Competitors 24
DiaSorin SpA, Key Employees 25
DiaSorin SpA, Other Locations 26
DiaSorin SpA, Subsidiaries 26

List of Figures
DiaSorin SpA, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
DiaSorin SpA, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
DiaSorin SpA, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
DiaSorin SpA, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
DiaSorin SpA, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
DiaSorin SpA, Medical Equipment, Deals by Type, 2012 to YTD 2018 6
DiaSorin SpA, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
DiaSorin SpA, Medical Equipment, Deals by Market, 2012 to YTD 2018 8

★海外企業調査レポート[DiaSorin SpA (DIA):医療機器:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Dana Incorporated:企業のM&A・事業提携・投資動向
    Dana Incorporated - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Dana Incorporated Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), div …
  • Alimera Sciences Inc (ALIM):医療機器:M&Aディール及び事業提携情報
    Summary Alimera Sciences Inc (Alimera) is a biopharmaceutical company that researches, develops and commercializes prescription ophthalmic pharmaceuticals. The company’s products include Iluvien, an intravitreal implant of fluocinolone acetonide which is indicated for the treatment of chronic diabet …
  • Merck KGaA (MRK)-医療機器分野:企業M&A・提携分析
    Summary Merck KGaA (Merck), a subsidiary of E. Merck KG, is a pharmaceutical and chemical company. It discovers, develops and manufactures prescription drugs to treat cancer, multiple sclerosis, and infertility and over-the-counter products for colds and pain; and develops liquid crystal mixtures, O …
  • TMRC Co Ltd-製薬・医療分野:企業M&A・提携分析
    Summary TMRC Co Ltd (TMRC) is a biopharmaceutical company that develops and markets anti-cancer and cancer related products. The company’s products include tamibarotene Am-80, TOS-80T, OMS0728, and others. Its tamibarotene is a synthetic retinoid, which is designed to develop drug-able properties of …
  • Intercept Pharmaceuticals Inc (ICPT):企業の財務・戦略的SWOT分析
    Intercept Pharmaceuticals Inc (ICPT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Jet Airways (India) Ltd.:企業の戦略・SWOT・財務情報
    Jet Airways (India) Ltd. - Strategy, SWOT and Corporate Finance Report Summary Jet Airways (India) Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Qatar Shipping Co:企業の戦略的SWOT分析
    Qatar Shipping Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Discovery Inc (DISCA):企業の財務・戦略的SWOT分析
    Discovery Inc (DISCA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Hertz Global Holdings Inc:企業のM&A・事業提携・投資動向
    Hertz Global Holdings Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Hertz Global Holdings Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisi …
  • Pharmagest Interactive SA (PHA):企業の財務・戦略的SWOT分析
    Summary Pharmagest Interactive SA (Pharmagest Interactive) is a technology company that develops and markets professional IT solutions for pharmacies and pharmaceutical industries. The company operates through four divisions such as pharmaceutical, fintech, e-health, and health and medico-social div …
  • Monster Worldwide Inc:企業の戦略的SWOT分析
    Monster Worldwide Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • MAB Discovery GmbH-製薬・医療分野:企業M&A・提携分析
    Summary MAB Discovery GmbH (MAB Discovery) is a drug discovery and development company that offers novel antibody therapeutics. The company produces monoclonal antibodies derived from rabbits and rats. It relies on natural immune response and state of the art B cell cloning techniques for the produc …
  • Lear Corp (LEA):企業の財務・戦略的SWOT分析
    Lear Corp (LEA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • City Holding Co (CHCO):企業の財務・戦略的SWOT分析
    City Holding Co (CHCO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • VistaGen Therapeutics Inc (VTGN):医療機器:M&Aディール及び事業提携情報
    Summary VistaGen Therapeutics Inc (VistaGen) is a clinical stage biopharmaceutical company that develops new generation medicines for depression and neuropsychiatric disorders. The company’s pipeline product, AV-101, currently under Phase 2 clinical development, is an oral N-methyl-D-aspartate recep …
  • Guangshen Railway Company Limited:企業の戦略・SWOT・財務情報
    Guangshen Railway Company Limited - Strategy, SWOT and Corporate Finance Report Summary Guangshen Railway Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Jarir Marketing Company:企業の戦略・SWOT・財務情報
    Jarir Marketing Company - Strategy, SWOT and Corporate Finance Report Summary Jarir Marketing Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Eternygen GmbH-製薬・医療分野:企業M&A・提携分析
    Summary Eternygen GmbH (Eternygen) focuses on research and development of innovative drugs for dietary-related metabolic diseases.The company’s product development portfolio includes novel small molecule inhibitors, developed against the sodium coupled citrate transporter NaCT. It focuses research o …
  • W. L. Gore & Associates Inc:企業の戦略的SWOT分析
    W. L. Gore & Associates Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …
  • Ternium SA:企業の戦略・SWOT・財務情報
    Ternium SA - Strategy, SWOT and Corporate Finance Report Summary Ternium SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆